Dimerix Limited (ASX: DXB) announced that its ACTION3 Phase 3 clinical trial has completed recruitment and dosing of its target ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE